SHERIDAN, WYOMING – November 08, 2024 – Sanofi, a leading global biopharmaceutical company, has announced outstanding results for the third quarter of 2024, showcasing robust financial performance and significant progress in its innovative product pipeline. The company's dedication to providing healthcare solutions for patients worldwide is reflected in its impressive double-digit sales growth and groundbreaking achievements in research and development.
Sanofi's Q3 2024 sales surged by 15.7% at constant exchange rates (CER), reaching €13,438 million. Business earnings per share (EPS) also saw a significant increase, rising by 12.2% on a reported basis and 17.6% at CER to reach €2.86. This strong performance was fueled by better-than-expected vaccine sales, particularly for influenza and Beyfortus (RSV), and the continued strong growth of Dupixent, the company's leading immunology drug.
Dupixent Continues its Impressive Growth Trajectory
Dupixent sales soared by 23.8% in Q3, reaching €3,476 million. This impressive growth is driven by strong demand across all approved indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Dupixent has also recently been approved as the first biologic medicine to treat COPD in the EU, China, and the US, expanding its reach to hundreds of thousands of patients.
Pipeline Successes Underscore Sanofi's Commitment to Innovation
Sanofi's dedication to research and development is evident in its robust product pipeline, which includes 78 projects across key therapeutic areas such as immunology, rare diseases, neurology, oncology, and vaccines.
During Q3, the company achieved four regulatory approvals for Dupixent in COPD and CRSwNP, and Sarclisa in multiple myeloma. Additionally, Sanofi announced four positive phase 3 data readouts for Dupixent in bullous pemphigoid and chronic spontaneous urticaria, tolebrutinib in secondary progressive multiple sclerosis, and Sarclisa in multiple myeloma. This progress highlights the company's commitment to addressing unmet medical needs.
Sanofi Sharpens Focus on Core Businesses
Sanofi has entered into exclusive negotiations with CD&R to transfer a controlling stake in Opella, its consumer healthcare business. This strategic move will enable the company to further concentrate on its core strengths in innovative medicines and vaccines.
Strong Performance Leads to Upgraded Guidance
Based on its strong Q3 performance, Sanofi has raised its 2024 business EPS guidance to growth of at least a low single-digit percentage at CER.
About Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving human health through science. The company provides potentially life-changing treatments for patients with rare diseases and innovative therapies for millions with common conditions. Sanofi's medicines and vaccines are available in over 100 countries worldwide, with a strong presence in both developed and emerging markets. The company is headquartered in Paris, France.